- Lobbying
- Edward AND Reno AND III
Lobbying Arrangements Results for 'Edward Reno Iii'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to the opioid crisis; Issues related to NIH funding; Issues related to wound care. |
MilanaPharm
|
Forbes-Tate | |||
Details Issues related to the opioid crisis. |
Virpax Pharmaceuticals
|
Forbes-Tate | |||
Details S. 1757, The AIM Act; H.R. 2597, The AIM Act Issues related to Global Warming |
Strathspey Crown, LLC
|
in-house lobbying | |||
Details Issues related to federal Information and Communications Technology (ICT) contracts. |
Goldman Edwards
|
Forbes-Tate | |||
Details Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry. |
Verde Technologies
|
Forbes-Tate | |||
Details Issues related to cosmetics. |
Evolus Beauty
|
Forbes-Tate | |||
Details Issues related to commercial solutions for an overactive bladder condition. Issues related to H.R. 925 - The Heroes Act. |
Urovant Sciences
|
Forbes-Tate | |||
Details Issues related to Biologics. |
AEON Biopharma
|
Forbes-Tate | |||
Details Issues relating to expansion of COVID-19 testing capacity across the country. |
PrivaPath Diagnostics, Inc. DBA Let's Get Checked, Inc.
|
Forbes-Tate | |||
Details Issues related to market access and COVID-19. |
Kahala Biosciences
|
Forbes-Tate | |||
Details Issues related to the advancement of research and development. |
Syndax Pharmaceuticals
|
Forbes-Tate | |||
Details Issues related to indoor agriculture. |
Grodan Inc.
|
Forbes-Tate | |||
Details Issues related to NIDA grants for the research and development of medical technology. Issues related to H.R. 925 - The Heroes Act. |
Abyrx, Inc.
|
Forbes-Tate | |||
Details Issues related to COVID-19 response. |
Primmune Therapeutics
|
Forbes-Tate | |||
Details Issues related to FDA approval and NIH funding issues. |
Sorrento Therapeutics, Inc.
|
Forbes-Tate | |||
Details Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending ... |
Emergent Biosolutions
|
Forbes-Tate | |||
Details Issues related to higher education. |
Jacksonville State University
Higher Educational Institution |
Forbes-Tate | |||
Details Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases. Issues related to Medicare and Medicaid reimbursement; Issues related to rare diseases; Issues related to new... |
Sarepta Therapeutics
|
Forbes-Tate | |||
Details Issues related to legislation to provide relief during the COVID-19 pandemic; Issues related to advanced research and development for COVID-19 response. Issues related to H.R. 925 - The Heroes Act. |
Bellerophon Therapeutics
|
Forbes-Tate | |||
Details Issues related to biomedical research and development; Issues related to pathogen surveillance. |
Bio-Rad Laboratories
|
Forbes-Tate | |||
Details Issues related to CARA implementation; Issues related to opioid abuse; Issues related to FDA; Issues related to FY 2018 Appropriations implementation; Issues related FY 2019 LHHS Appropriations (H... |
Adapt Pharma Inc.
|
Forbes-Tate | |||
Details Issues related to agriculture and technology in emerging industries; Issues pertaining to track and trace technology. Issues related to agriculture and technology in emerging industries. |
Metrc LLC
|
Forbes-Tate | |||
Details Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169). |
Halozyme Therapeutics, Inc.
|
Forbes-Tate | |||
Details Issues related to Medicaid and COVID-19. |
Molina Healthcare, Inc.
|
Forbes-Tate | |||
Details Issues related to PFAS remediation. |
Regenesis
|
Forbes-Tate | |||
Details Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of C... |
Novartis, Inc.
|
Forbes-Tate | |||
Details Issues related to rare disease, drug development, reimbursement, and market access. |
Ultragenyx Pharmaceutical
|
Forbes-Tate | |||
Details Issues related to Insulin pricing, Issues regarding the 340B Drug Pricing Program. Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Ant... |
Lilly USA, LLC
|
Forbes-Tate | |||
Details Issues related to prescription drug pricing; Issues related to proposed regulations affecting Medicare Part D. Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and result... |
Lundbeck LLC
|
Forbes-Tate | |||
Details Federal bankruptcy related issues that impact Puerto Rico and/or the municipal bond market; Issues related to Municipal bond policies; Issues related to passive foreign Investment Companies; Issues... |
Assured Guaranty Municipal Corp.
|
Forbes-Tate | |||
Details Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness. Healthcare initiatives related to novel antibody technology platform. Issues related to p... |
Vir Biotechnology, Inc.
|
Forbes-Tate | |||
Details Issues related to FY 2022 Defense Appropriations; Issues related to funding for university research and UARCs. Issues related to emergency funding for institutions of higher education in H.R. 1319 ... |
University of Southern California
|
Forbes-Tate |